Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Myocardial infarction (MI) is a major contributor to morbidity and mortality in China. The goal of this interventional, randomised controlled clinical trial is to evaluate the effectiveness and safety of a single administration of Nivolumab to the patients presenting with an acute anterior ST-segmental elevated myocardial infarction. Researchers will investigate if Nivolumab treatment can effectively and safely reduce infarct size as well as improve cardiac function of the patients with acute myocardial infarction.
The efficacy and safety of nivolumab as compared with placebo in the treatment of acute anterior ST segment elevation myocardial infarction are not known. In this phase 1/2, randomized, placebo-controlled, open-label trial, we randomly assigned adults with acute anterior ST segment elevation myocardial infarction to receive either nivolumab (5mg/kg for single administration) or placebo. The primary end points were difference in infarct size/LV mass% from baseline to 3 months after Nivolumab administration and the incidence of adverse events during 3 months after Nivolumab administration. Secondary end points included difference in LVEF%, LVESV/Body surface area, LVEDV/Body surface area, Trponin T and proBNP from baseline to 3 months after Nivolumab administration.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Interventional drug treatment group | Experimental | The participants receive Nivolumab treatment. The active drug Nivolumab will be administered at a standard dose (5mg/kg) dissolved in 100ml 0.9%NaCl solution. Nivolumab was given at a rate of 15-25 drops per minute, and the intravenous infusion time exceeded 1 hour. |
|
| Placebo treatment group | Placebo Comparator | The participants receive placebo treatment. Patients assigned to the placebo treatment group will receive an intravenous infusion of 100 ml 0.9% NaCl solution at a rate of 15-25 drops/min for an IV infusion duration of more than 1 hour. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Nivolumab | Drug | Single administration of Nivolumab on the third day of revascularization after acute anterior ST segment elevation myocardial infarction. The active drug Nivolumab will be administered at a standard dose (5mg/kg) dissolved in 100ml 0.9%NaCl solution. Nivolumab was given at a rate of 15-25 drops per minute, and the intravenous infusion time exceeded 1 hour. |
| Measure | Description | Time Frame |
|---|---|---|
| ∆Infarct size/Left Ventricular mass% | Difference in Infarct size/Left ventricular mass% from baseline to 3 months after Nivolumab administration. | 3 months |
| The incidence of adverse events | The incidence of adverse events during 3 months after Nivolumab treatment. | up to 3 months |
| Measure | Description | Time Frame |
|---|---|---|
| ∆Left ventricle ejection fraction% | Difference in Left ventricle ejection fraction% from baseline to 3 months after Nivolumab administration. | 3 months |
| ∆Left ventricle end systolic volume/Body surface area |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Yinchuan Xu, PhD | Contact | 86-13968126628 | lsyrmxyc@126.com | |
| Changle Ke, PhD | Contact | 86-15757102667 | keheart@zju.edu.cn |
| Name | Affiliation | Role |
|---|---|---|
| Xinyang Hu, PhD | 2nd Affiliated Hospital, School of Medicine, Zhejiang University, China | Principal Investigator |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D000077594 | Nivolumab |
| ID | Term |
|---|---|
| D061067 | Antibodies, Monoclonal, Humanized |
| D000911 | Antibodies, Monoclonal |
| D000906 | Antibodies |
| D007136 | Immunoglobulins |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| Placebo | Other | Single administration of Placebo on the third day of revascularization after acute anterior ST segment elevation myocardial infarction. Patients assigned to the placebo treatment group will receive an intravenous infusion of 100 ml 0.9% NaCl solution at a rate of 15-25 drops/min for an IV infusion duration of more than 1 hour. |
|
Difference in Left ventricle end systolic volume/Body surface area from baseline to 3 months after Nivolumab administration.
| 3 months |
| ∆Left ventricle end diastolic volume/Body surface area | Difference in Left ventricle end diastolic volume/Body surface area from baseline to 3 months after Nivolumab administration. | 3 months |
| ∆Troponin T | Difference in concentration of Troponin T from baseline to 3 months after Nivolumab administration. | 3 months |
| ∆proBNP | Difference in concentration of proBNP from baseline to 3 months after Nivolumab administration. | 3 months |
| D007162 |
| Immunoproteins |
| D001798 | Blood Proteins |
| D011506 | Proteins |
| D000602 | Amino Acids, Peptides, and Proteins |
| D012712 | Serum Globulins |
| D005916 | Globulins |